Literature DB >> 11554404

New sensitive liquid chromatography method coupled with tandem mass spectrometric detection for the clinical analysis of vinorelbine and its metabolites in blood, plasma, urine and faeces.

J C Van Heugen1, J De Graeve, G Zorza, C Puozzo.   

Abstract

A new sensitive and specific liquid chromatographic method coupled with tandem mass spectrometric detection was set up and validated for the simultaneous quantitation of vinorelbine, its main metabolite, 4-O-deacetylvinorelbine and two other minor metabolites, 20'-hydroxyvinorelbine and vinorelbine 6'-oxide. All these compounds, including vinblastine (used as internal standard) were deproteinised from blood, plasma and faeces (only diluted in urine), analysed on a cyano column and detected on a Micromass Quattro II system in the positive ion mode after ionisation, using an electrospray ion source. Under tandem mass spectrometry conditions, the specific product ions led one to accurately quantify vinorelbine and its metabolites in all biological fluids. In whole blood, linearity was assessed up to 200 ng/ml for vinorelbine and up to 50 ng/ml for the metabolites. The limit of quantitation was validated at 250 pg/ml for both vinorelbine and 4-O-deacetylvinorelbine. In the other biological media, the linearity was assessed within a same range and the limit of quantitation was adjusted according to the expected concentrations of each compound. This method was initially developed in order to identify the metabolite structures and to elucidate the metabolic pathway of vinorelbine. Thanks to its high sensitivity, this method has enabled the quantitation of vinorelbine and all its metabolites in whole blood over 168 h (i.e., 4-5 elimination half lives) whilst the previous liquid chromatographic methods allowed their measurement for a maximum of 48-72 h. Therefore, using this method has improved the reliability of the pharmacokinetic data analysis of vinorelbine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11554404     DOI: 10.1016/s0021-9673(01)00993-1

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  8 in total

Review 1.  Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.

Authors:  Monique P Curran; Greg L Plosker
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine.

Authors:  Ariel R Topletz; Jennifer B Dennison; Robert J Barbuch; Chad E Hadden; Stephen D Hall; Jamie L Renbarger
Journal:  Drug Metab Dispos       Date:  2013-06-18       Impact factor: 3.922

3.  A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer.

Authors:  Yunpeng Yang; Jianhua Chang; Cheng Huang; Yiping Zhang; Jie Wang; Yongqian Shu; Jean Philippe Burillon; Marcello Riggi; Aurélie Petain; Pierre Ferre; Ying Liang; Li Zhang
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

4.  Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.

Authors:  E Brain; N Isambert; F Dalenc; V Diéras; J Bonneterre; K Rezai; M Jimenez; F Mefti-Lacheraf; E Cottura; P Tresca; L Vanlemmens; C Mahier-Aït Oukhatar; F Lokiec; P Fumoleau
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640

5.  Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis.

Authors:  Aurélie Pétain; Dafang Zhong; Xiaoyan Chen; Zhang Li; Shao Zhimin; Jiang Zefei; Grégoire Zorza; Pierre Ferré
Journal:  Cancer Chemother Pharmacol       Date:  2019-05-27       Impact factor: 3.333

6.  Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.

Authors:  Evangelos Briasoulis; Gerasimos Aravantinos; George Kouvatseas; Periklis Pappas; Eirini Biziota; Ioannis Sainis; Thomas Makatsoris; Ioannis Varthalitis; Ioannis Xanthakis; Antonios Vassias; George Klouvas; Ioannis Boukovinas; George Fountzilas; Kostantinos N Syrigos; Haralambos Kalofonos; Epaminontas Samantas
Journal:  BMC Cancer       Date:  2013-05-29       Impact factor: 4.430

7.  Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules.

Authors:  Natalia Sutiman; Zhenxian Zhang; Eng Huat Tan; Mei Kim Ang; Shao-Weng Daniel Tan; Chee Keong Toh; Quan Sing Ng; Balram Chowbay; Wan-Teck Lim
Journal:  PLoS One       Date:  2016-05-02       Impact factor: 3.240

8.  Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells.

Authors:  Eirini Biziota; Evangelos Briasoulis; Leonidas Mavroeidis; Marios Marselos; Adrian L Harris; Periklis Pappas
Journal:  Anticancer Drugs       Date:  2016-03       Impact factor: 2.248

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.